Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program

por Ajluni, Nevin, Dar, Moahad, Xu, John, Neidert, Adam H, Oral, Elif A
Publicado 2016

2287 ECG and echo characteristics in familial partial lipodystrophy: The impact of Lamin A variants

por Eldin, Abdelwahab J., Meral, Rasimcan, Neidert, Adam H., Rus, Diana, Hench, Rita, Oral, Hakan, Oral, Elif A.
Publicado 2018

Diagnosis of acquired generalized lipodystrophy in a single patient with T-cell lymphoma and no exposure to Metreleptin

por Esfandiari, Nazanene H., Rubenfire, Melvyn, Neidert, Adam H., Hench, Rita, Eldin, Abdelwahab Jalal, Meral, Rasimcan, Oral, Elif A.
Publicado 2019

The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide

por Akinci, Baris, Meral, Rasimcan, Rus, Diana, Hench, Rita, Neidert, Adam H, DiPaola, Frank, Westerhoff, Maria, Taylor, Simeon I, Oral, Elif A
Publicado 2020

Iron parameters in patients with partial lipodystrophy and impact of exogenous leptin therapy

por Akinci, Efe Y, Boutros, Sabine, Ryan, Benjamin J, Sargin, Pinar, Akinci, Baris, Neidert, Adam H, Hench, Rita, Horowitz, Jeffrey F, Oral, Elif A
Publicado 2021